VIRGINIA STATE BOARD OF PHARMACY ET
AL. v.
VIRGINIA CITIZENS CONSUMER COUNCIL, INC., ET AL.
APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE EASTERN
DISTRICT OF VIRGINIA.
No. 74-895.
Argued November 11, 1975.
Decided May 24, 1976.
Appellees, as consumers of prescription
drugs, brought suit against the Virginia State Board of
Pharmacy and its individual members, appellants herein,
challenging the validity under the First and Fourteenth
Amendments of a Virginia statute declaring it unprofessional
conduct for a licensed pharmacist to advertise the prices
of prescription drugs. A three-judge District Court declared
the statute void and enjoined appellants from enforcing
it.
Held:
1. Any First Amendment protection enjoyed
by advertisers seeking to disseminate prescription drug
price information is also enjoyed, and thus may be asserted,
by appellees as recipients of such information. Pp. 756-757.
2. "Commercial speech" is not
wholly outside the protection of the First and Fourteenth
Amendments, and the Virginia statute is therefore invalid.
Pp. 761-773.
(a) That the advertiser's interest in a
commercial advertisement is purely economic does not disqualify
him from protection under the First and Fourteenth Amendments.
Both the individual consumer and society in general may
have strong interests in the free flow of commercial information.
Pp. 762-765.
(b) The ban on advertising prescription
drug prices cannot be justified on the basis of the State's
interest in maintaining the professionalism of its licensed
pharmacists; the State is free to require whatever professional
standards it wishes of its pharmacists, and may subsidize
them or protect them from competition in other ways, but
it may not do so by keeping the public in ignorance of
the lawful terms that competing pharmacists are offering.
Pp. 766-770.
(c) Whatever may be the bounds of time,
place, and manner restrictions on commercial speech, they
are plainly exceeded by [425 U.S. 748, 749] the Virginia
statute, which singles out speech of a particular content
and seeks to prevent its dissemination completely. Pp.
770-771.
(d) No claim is made that the prohibited
prescription drug advertisements are false, misleading,
or propose illegal transactions, and a State may not suppress
the dissemination of concededly truthful information about
entirely lawful activity, fearful of that information's
effect upon its disseminators and its recipients. Pp.
771-773.
373 F. Supp. 683, affirmed.
BLACKMUN, J., delivered the opinion of the Court, in which
BURGER, C. J., and BRENNAN, STEWART, WHITE, MARSHALL,
and POWELL, JJ., joined. BURGER, C. J., post, p. 773,
and STEWART, J., post, p. 775, filed concurring opinions.
REHNQUIST, J., filed a dissenting opinion, post, p. 781.
STEVENS, J., took no part in the consideration or decision
of the case.
Anthony F. Troy, Chief Deputy Attorney General
of Virginia, argued the cause for appellants. With him
on the brief were Andrew P. Miller, Attorney General,
and D. Patrick Lacy, Jr., Deputy Attorney General.
Alan B. Morrison argued the cause and filed
a brief for appellees. *
[ Footnote * ] Briefs of amici curiae urging affirmance
were filed by Alfred Miller and Stephen L. Solomon for
the American Association of Retired Persons et al.; by
Gilbert H. Weil, Philip B. Kurland, and Alan L. Unikel
for the Association of National Advertisers, Inc.; and
by Harold Rosenwald for Osco Drug, Inc.
MR. JUSTICE BLACKMUN delivered the opinion
of the Court.
The plaintiff-appellees in this case attack,
as violative of the First and Fourteenth Amendments, 1
that portion of 54-524.35 of Va. Code Ann. (1974), which
provides that a pharmacist licensed in Virginia is guilty
of unprofessional [425 U.S. 748, 750] conduct if he "(3)
publishes, advertises or promotes, directly or indirectly,
in any manner whatsoever, any amount, price, fee, premium,
discount, rebate or credit terms . . . for any drugs which
may be dispensed only by prescription." 2 The three-judge
District Court declared the quoted portion of the statute
"void and of no effect," Jurisdictional Statement,
App. 1, and enjoined the defendant-appellants, the Virginia
State Board of Pharmacy and the individual members of
that Board, from enforcing it. 373 F. Supp. 683 (ED Va.
1974). We noted probable jurisdiction of the appeal. 420
U.S. 971 (1975).
I
Since the challenged restraint is one that peculiarly
concerns the licensed pharmacist in Virginia, we begin
with a description of that profession as it exists under
Virginia law.
The "practice of pharmacy" is
statutorily declared to be "a professional practice
affecting the public health, safety and welfare,"
and to be "subject to regulation and control in the
public interest." Va. Code Ann. 54-524.2 (a) (1974).
3 Indeed, the practice is subject to extensive [425 U.S.
748, 751] regulation aimed at preserving high professional
standards. The regulatory body is the appellant Virginia
State Board of Pharmacy. The Board is broadly charged
by statute with various responsibilities, including the
"[m]aintenance of the quality, quantity, integrity,
safety and efficacy of drugs or devices distributed, dispensed
or administered." 54-524.16 (a). It also is to concern
itself with "[m]aintaining the integrity of, and
public confidence in, the profession and improving the
delivery of quality pharmaceutical services to the citizens
of Virginia." 54-524.16 (d). The Board is empowered
to "make such bylaws, rules and regulations . . .
as may be necessary for the lawful exercise of its powers."
54-524.17.
The Board is also the licensing authority.
It may issue a license, necessary for the practice of
pharmacy in the State, only upon evidence that the applicant
is "of good moral character," is a graduate
in pharmacy of a school approved by the Board, and has
had "a suitable period of experience [the period
required not to exceed 12 months] acceptable to the Board."
54-524.21. The applicant must pass the examination prescribed
by the Board. Ibid. One approved school is the School
of Pharmacy of the Medical College of Virginia, where
the curriculum is for three years following two years
of college. Prescribed prepharmacy courses, such as biology
and chemistry, are to be taken in college, and study requirements
at the school itself include courses in organic chemistry,
biochemistry, comparative anatomy, physiology, and pharmacology.
Students are also trained in the ethics of the profession,
and there is some clinical experience in the school's
hospital pharmacies and in the medical center operated
by the Medical College. This [425 U.S. 748, 752] is "a
rigid, demanding curriculum in terms of what the pharmacy
student is expected to know about drugs." 4
Once licensed, a pharmacist is subject to
a civil monetary penalty, or to revocation or suspension
of his license, if the Board finds that he "is not
of good moral character," or has violated any of
a number of stated professional standards (among them
that he not be "negligent in the practice of pharmacy"
or have engaged in "fraud or deceit upon the consumer
. . . in connection with the practice of pharmacy"),
or is guilty of "unprofessional conduct." 54-524.22:1.
"Unprofessional conduct" is specifically defined
in 54-524.35, n. 2, supra, the third numbered phrase of
which relates to advertising of the price for any prescription
drug, and is the subject of this litigation.
Inasmuch as only a licensed pharmacist may
dispense prescription drugs in Virginia, 54-524.48, 5
advertising or other affirmative dissemination of prescription
drug price information is effectively forbidden in the
State. Some pharmacies refuse even to quote prescription
drug prices over the telephone. The Board's position,
however, is that this would not constitute an unprofessional
publication. 6 It is clear, nonetheless, that all advertising
of such prices, in the normal sense, is forbidden. The
prohibition does not extend to nonprescription drugs,
but neither is it confined to prescriptions that the pharmacist
compounds himself. Indeed, about 95% of all prescriptions
now are filled with dosage forms prepared by the pharmaceutical
manufacturer. 7 [425 U.S. 748, 753]
II
This is not the first challenge to the constitutionality
of 54-524.35 and what is now its third-numbered phrase.
Shortly after the phrase was added to the statute in 1968,
8 a suit seeking to enjoin its operation was instituted
by a drug retailing company and one of its pharmacists.
Although the First Amendment was invoked, the challenge
appears to have been based primarily on the Due Process
and Equal Protection Clauses of the Fourteenth Amendment.
In any event, the prohibition on drug price advertising
was upheld. Patterson Drug Co. v. Kingery, 305 F. Supp.
821 (WD Va. 1969). The threejudge court did find that
the dispensation of prescription drugs "affects the
public health, safety and welfare." Id., at 824-825.
No appeal was taken.
The present, and second, attack on the statute
is one made not by one directly subject to its prohibition,
that is, a pharmacist, but by prescription drug consumers
who claim that they would greatly benefit if the prohibition
were lifted and advertising freely allowed. The plaintiffs
are an individual Virginia resident who suffers from diseases
that require her to take prescription drugs on a daily
basis, 9 and two nonprofit organizations. 10 Their [425
U.S. 748, 754] claim is that the First Amendment entitles
the user of prescription drugs to receive information
that pharmacists wish to communicate to them through advertising
and other promotional means, concerning the prices of
such drugs.
Certainly that information may be of value.
Drug prices in Virginia, for both prescription and nonprescription
items, strikingly vary from outlet to outlet even within
the same locality. It is stipulated, for example, that
in Richmond "the cost of 40 Achromycin tablets ranges
from $2.59 to $6.00, a difference of 140% [sic],"
and that in the Newport News-Hampton area the cost of
tetracycline ranges from $1.20 to $9.00, a difference
of 650%. 11
The District Court seized on the identity
of the plaintiff-appellees as consumers as a feature distinguishing
the [425 U.S. 748, 755] present case from Patterson Drug
Co. v. Kingery, supra. Because the unsuccessful plaintiffs
in that earlier case were pharmacists, the court said,
"theirs was a prima facie commercial approach,"
373 F. Supp., at 686. The present plaintiffs, on the other
hand, were asserting an interest in their own health that
was "fundamentally deeper than a trade consideration."
Ibid. In the District Court's view, the expression in
Valentine v. Chrestensen, 316 U.S. 52, 54 -55 (1942),
to the effect that "purely commercial advertising"
is not protected had been tempered, by later decisions
of this Court, to the point that First Amendment interests
in the free flow of price information could be found to
outweigh the countervailing interests of the State. The
strength of the interest in the free flow of drug price
information was borne out, the court felt, by the fact
that three States by court decision had struck down their
prohibitions on drug price advertising. Florida Board
of Pharmacy v. Webb's City, Inc., 219 So.2d 681 (Fla.
1969); Maryland Board of Pharmacy v. Sav-A-Lot, Inc.,
270 Md. 103. 311 A. 2d 242 (1973); Pennsylvania State
Board of Pharmacy v. Pastor, 441 Pa. 186, 272 A. 2d 487
(1971). 12 The District Court recognized that this Court
had upheld - against federal constitutional challenges
other than on First Amendment grounds - state restrictions
[425 U.S. 748, 756] on the advertisement of prices for
optometrists' services, Head v. New Mexico Board, 374
U.S. 424 (1963), for eyeglass frames, Williamson v. Lee
Optical Co., 348 U.S. 483 (1955), and for dentists' services,
Semler v. Dental Examiners, 294 U.S. 608 (1935). 13 The
same dangers of abuse and deception were not thought to
be present, however, when the advertised commodity was
prescribed by a physician for his individual patient and
was dispensed by a licensed pharmacist. The Board failed
to justify the statute adequately, and it had to fall.
373 F. Supp., at 686-687.
III
The question first arises whether, even assuming that
First Amendment protection attaches to the flow of drug
price information, it is a protection enjoyed by the appellees
as recipients of the information, and not solely, if at
all, by the advertisers themselves who seek to disseminate
that information.
Freedom of speech presupposes a willing
speaker. But where a speaker exists, as is the case here,
14 the protection afforded is to the communication, to
its source and to its recipients both. This is clear from
the decided cases. In Lamont v. Postmaster General, 381
U.S. 301 (1965), the Court upheld the First Amendment
rights of citizens to receive political publications sent
from abroad. [425 U.S. 748, 757] More recently, in Kleindienst
v. Mandel, 408 U.S. 753, 762 -763 (1972), we acknowledged
that this Court has referred to a First Amendment right
to "receive information and ideas," and that
freedom of speech "`necessarily protects the right
to receive.'" And in Procunier v. Martinez, 416 U.S.
396, 408 -409 (1974), where censorship of prison inmates'
mail was under examination, we thought it unnecessary
to assess the First Amendment rights of the inmates themselves,
for it was reasoned that such censorship equally infringed
the rights of noninmates to whom the correspondence was
addressed. There are numerous other expressions to the
same effect in the Court's decisions. See, e. g., Red
Lion Broadcasting Co. v. FCC, 395 U.S. 367, 390 (1969);
Stanley v. Georgia, 394 U.S. 557, 564 (1969); Griswold
v. Connecticut, 381 U.S. 479, 482 (1965); Marsh v. Alabama,
326 U.S. 501, 505 (1946); Thomas v. Collins, 323 U.S.
516, 534 (1945); Martin v. Struthers, 319 U.S. 141, 143
(1943). If there is a right to advertise, there is a reciprocal
right to receive the advertising, and it may be asserted
by these appellees. 15 [425 U.S. 748, 758]
IV
The appellants contend that the advertisement of prescription
drug prices is outside the protection of the First Amendment
because it is "commercial speech." There can
be no question that in past decisions the Court has given
some indication that commercial speech is unprotected.
In Valentine v. Chrestensen, supra, the Court upheld a
New York statute that prohibited the distribution of any
"handbill, circular . . . or other advertising matter
whatsoever in or upon any street." The Court concluded
that, although the First Amendment would forbid the banning
of all communication by handbill in the public thoroughfares,
it imposed "no such restraint on government as respect
purely commercial advertising." 316 U.S., at 54 .
Further support for a "commercial speech" exception
to the First Amendment may perhaps be found in Breard
v. Alexandria, 341 U.S. 622 (1951), where the Court upheld
a conviction for violation of an ordinance prohibiting
door-to-door solicitation of magazine subscriptions. The
Court reasoned: "The selling . . . brings into the
transaction a commercial feature," and it distinguished
Martin v. Struthers, supra, where it had reversed a conviction
for door-to-door distribution of leaflets publicizing
a religious meeting, as a case involving "no element
of the commercial." 341 U.S., at 642 -643. Moreover,
the Court several times has stressed that communications
to which First Amendment protection was given were not
"purely commercial." New York Times Co. v. Sullivan,
376 U.S. 254, 266 [425 U.S. 748, 759] (1964); Thomas v.
Collins, 323 U.S., at 533 ; Murdock v. Pennsylvania, 319
U.S. 105, 111 (1943); Jamison v. Texas, 318 U.S. 413,
417 (1943).
Since the decision in Breard, however, the
Court has never denied protection on the ground that the
speech in issue was "commercial speech." That
simplistic approach, which by then had come under criticism
or was regarded as of doubtful validity by Members of
the Court, 16 was avoided in Pittsburgh Press Co. v. Human
Relations Comm'n, 413 U.S. 376 (1973). There the Court
upheld an ordinance prohibiting newspapers from listing
employment advertisements in columns according to whether
male or female employees were sought to be hired. The
Court, to be sure, characterized the advertisements as
"classic examples of commercial speech," id.,
at 385, and a newspaper's printing of the advertisements
as of the same character. The Court, however, upheld the
ordinance on the ground that the restriction it imposed
was permissible because the discriminatory hirings proposed
by the advertisements, and by their newspaper layout,
were themselves illegal.
Last Term, in Bigelow v. Virginia, 421 U.S.
809 (1975), the notion of unprotected "commercial
speech" all but passed from the scene. We reversed
a conviction for violation of a Virginia statute that
made the circulation of any publication to encourage or
promote the [425 U.S. 748, 760] processing of an abortion
in Virginia a misdemeanor. The defendant had published
in his newspaper the availability of abortions in New
York. The advertisement in question, in addition to announcing
that abortions were legal in New York, offered the services
of a referral agency in that State. We rejected the contention
that the publication was unprotected because it was commercial.
Chrestensen's continued validity was questioned, and its
holding was described as "distinctly a limited one"
that merely upheld "a reasonable regulation of the
manner in which commercial advertising could be distributed."
421 U.S., at 819 . We concluded that "the Virginia
courts erred in their assumptions that advertising, as
such, was entitled to no First Amendment protection,"
and we observed that the "relationship of speech
to the marketplace of products or of services does not
make it valueless in the marketplace of ideas." Id.,
at 825-826.
Some fragment of hope for the continuing
validity of a "commercial speech" exception
arguably might have persisted because of the subject matter
of the advertisement in Bigelow. We noted that in announcing
the availability of legal abortions in New York, the advertisement
"did more than simply propose a commercial transaction.
It contained factual material of clear `public interest.'"
Id., at 822. And, of course, the advertisement related
to activity with which, at least in some respects, the
State could not interfere. See Roe v. Wade, 410 U.S. 113
(1973); Doe v. Bolton, 410 U.S. 179 (1973). Indeed, we
observed: "We need not decide in this case the precise
extent to which the First Amendment permits regulation
of advertising that is related to activities the State
may legitimately regulate or even prohibit." 421
U.S., at 825 .
Here, in contrast, the question whether
there is a First Amendment exception for "commercial
speech" is [425 U.S. 748, 761] squarely before us.
Our pharmacist does not wish to editorialize on any subject,
cultural, philosophical, or political. He does not wish
to report any particularly newsworthy fact, or to make
generalized observations even about commercial matters.
The "idea" he wishes to communicate is simply
this: "I will sell you the X prescription drug at
the Y price." Our question, then, is whether this
communication is wholly outside the protection of the
First Amendment.
V
We begin with several propositions that already are settled
or beyond serious dispute. It is clear, for example, that
speech does not lose its First Amendment protection because
money is spent to project it, as in a paid advertisement
of one form or another. Buckley v. Valeo, 424 U.S. 1,
35 -59 (1976); Pittsburgh Press Co. v. Human Relations
Comm'n, 413 U.S., at 384 ; New York Times Co. v. Sullivan,
376 U.S., at 266 . Speech likewise is protected even though
it is carried in a form that is "sold" for profit,
Smith v. California, 361 U.S. 147, 150 (1959) (books);
Joseph Burstyn, Inc. v. Wilson, 343 U.S. 495, 501 (1952)
(motion pictures); Murdock v. Pennsylvania, 319 U.S.,
at 111 (religious literature), and even though it may
involve a solicitation to purchase or otherwise pay or
contribute money. New York Times Co. v. Sullivan, supra;
NAACP v. Button, 371 U.S. 415, 429 (1963); Jamison v.
Texas, 318 U.S., at 417 ; Cantwell v. Connecticut, 310
U.S. 296, 306 -307 (1940).
If there is a kind of commercial speech
that lacks all First Amendment protection, therefore,
it must be distinguished by its content. Yet the speech
whose content deprives it of protection cannot simply
be speech on a commercial subject. No one would contend
that our pharmacist may be prevented from being heard
on [425 U.S. 748, 762] the subject of whether, in general,
pharmaceutical prices should be regulated, or their advertisement
forbidden. Nor can it be dispositive that a commercial
advertisement is noneditorial, and merely reports a fact.
Purely factual matter of public interest may claim protection.
Bigelow v. Virginia, 421 U.S., at 822 ; Thornhill v. Alabama,
310 U.S. 88, 102 (1940).
Our question is whether speech which does
"no more than propose a commercial transaction,"
Pittsburgh Press Co. v. Human Relations Comm'n, 413 U.S.,
at 385 , is so removed from any "exposition of ideas,"
Chaplinsky v. New Hampshire, 315 U.S. 568, 572 (1942),
and from "`truth, science, morality, and arts in
general, in its diffusion of liberal sentiments on the
administration of Government,'" Roth v. United States,
354 U.S. 476, 484 (1957), that it lacks all protection.
Our answer is that it is not.
Focusing first on the individual parties
to the transaction that is proposed in the commercial
advertisement, we may assume that the advertiser's interest
is a purely economic one. That hardly disqualifies him
from protection under the First Amendment. The interests
of the Contestants in a labor dispute are primarily economic,
but it has long been settled that both the employee and
the employer are protected by the First Amendment when
they express themselves on the merits of the dispute in
order to influence its outcome. See e. g., NLRB v. Gissel
Packing Co., 395 U.S. 575, 617 -618 (1969); NLRB v. Virginia
Electric & Power Co., 314 U.S. 469, 477 (1941); AFL
v. Swing, 312 U.S. 321, 325 -326 (1941); Thornhill v.
Alabama, 310 U.S., at 102 . We know of no requirement
that, in order to avail themselves of First Amendment
protection, the parties to a labor dispute need address
themselves to the merits of unionism in general [425 U.S.
748, 763] or to any subject beyond their immediate dispute.
17 It was observed in Thornhill that "the practices
in a single factory may have economic repercussions upon
a whole region and affect widespread systems of marketing."
Id., at 103. Since the fate of such a "single factory"
could as well turn on its ability to advertise its product
as on the resolution of its labor difficulties, we see
no satisfactory distinction between the two kinds of speech.
As to the particular consumer's interest
in the free flow of commercial information, that interest
may be as keen, if not keener by far, than his interest
in the day's most urgent political debate. Appellees'
case in this respect is a convincing one. Those whom the
suppression of prescription drug price information hits
the hardest are the poor, the sick, and particularly the
aged. A disproportionate amount of their income tends
to be spent on prescription drugs; yet they are the least
able to learn, by shopping from pharmacist to pharmacist,
where their scarce dollars are best spent. 18 When drug
prices [425 U.S. 748, 764] vary as strikingly as they
do, information as to who is charging what becomes more
than a convenience. It could mean the alleviation of physical
pain or the enjoyment of basic necessities.
Generalizing, society also may have a strong
interest in the free flow of commercial information. Even
an individual advertisement, though entirely "commercial,"
may be of general public interest. The facts of decided
cases furnish illustrations: advertisements stating that
referral services for legal abortions are available, Bigelow
v. Virginia, supra; that a manufacturer of artificial
furs promotes his product as an alternative to the extinction
by his competitors of fur-bearing mammals, see Fur Information
& Fashion Council, Inc. v. E. F. Timme & Son,
364 F. Supp. 16 (SDNY 1973); and that a domestic producer
advertises his product as an alternative to imports that
tend to deprive American residents of their jobs, cf.
Chicago Joint Board v. Chicago Tribune Co., 435 F.2d 470
(CA7 1970), cert. denied, 402 U.S. 973 (1971). Obviously,
not all commercial messages contain the same or even a
very great public interest element. There are few to which
such an element, however, could not be added. Our pharmacist,
for example, could cast himself as a commentator on store-to-store
disparities [425 U.S. 748, 765] in drug prices, giving
his own and those of a competitor as proof. We see little
point in requiring him to do so, and little difference
if he does not.
Moreover, there is another consideration
that suggests that no line between publicly "interesting"
or "important" commercial advertising and the
opposite kind could ever be drawn. Advertising, however
tasteless and excessive it sometimes may seem, is nonetheless
dissemination of information as to who is producing and
selling what product, for what reason, and at what price.
So long as we preserve a predominantly free enterprise
economy, the allocation of our resources in large measure
will be made through numerous private economic decisions.
It is a matter of public interest that those decisions,
in the aggregate, be intelligent and well informed. To
this end, the free flow of commercial information is indispensable.
See Dun & Bradstreet, Inc. v. Grove, 404 U.S. 898,
904 -906 (1971) (Douglas, J., dissenting from denial of
certiorari). See also FTC v. Procter & Gamble Co.,
386 U.S. 568, 603 -604 (1967) (Harlan, J., concurring).
And if it is indispensable to the proper allocation of
resources in a free enterprise system, it is also indispensable
to the formation of intelligent opinions as to how that
system ought to be regulated or altered. Therefore, even
if the First Amendment were thought to be primarily an
instrument to enlighten public decisionmaking in a democracy,
19 we could not say that the free flow of information
does not serve that goal. 20 [425 U.S. 748, 766]
Arrayed against these substantial individual
and societal interests are a number of justifications
for the advertising ban. These have to do principally
with maintaining a high degree of professionalism on the
part of licensed pharmacists. 21 Indisputably, the State
has a strong interest in maintaining that professionalism.
It is exercised in a number of ways for the consumer's
benefit. There is the clinical skill involved in the compounding
of drugs, although, as has been noted, these now make
up only a small percentage of the prescriptions filled.
Yet, even with respect to manufacturer-prepared compounds,
there is room for the pharmacist [425 U.S. 748, 767] to
serve his customer well or badly. Drugs kept too long
on the shelf may lose their efficacy or become adulterated.
They can be packaged for the user in such a way that the
same results occur. The expertise of the pharmacist may
supplement that of the prescribing physician, if the latter
has not specified the amount to be dispensed or the directions
that are to appear on the label. The pharmacist, a specialist
in the potencies and dangers of drugs, may even be consulted
by the physician as to what to prescribe. He may know
of a particular antagonism between the prescribed drug
and another that the customer is or might be taking, or
with an allergy the customer may suffer. The pharmacist
himself may have supplied the other drug or treated the
allergy. Some pharmacists, concededly not a large number,
"monitor" the health problems and drug consumptions
of customers who come to them repeatedly. 22 A pharmacist
who has a continuous relationship with his customer is
in the best position, of course, to exert professional
skill for the customer's protection.
Price advertising, it is argued, will place
in jeopardy the pharmacist's expertise and, with it, the
customer's health. It is claimed that the aggressive price
competition that will result from unlimited advertising
will make it impossible for the pharmacist to supply professional
services in the compounding, handling, and dispensing
[425 U.S. 748, 768] of prescription drugs. Such services
are time consuming and expensive; if competitors who economize
by eliminating them are permitted to advertise their resulting
lower prices, the more painstaking and conscientious pharmacist
will be forced either to follow suit or to go out of business.
It is also claimed that prices might not necessarily fall
as a result of advertising. If one pharmacist advertises,
others must, and the resulting expense will inflate the
cost of drugs. It is further claimed that advertising
will lead people to shop for their prescription drugs
among the various pharmacists who offer the lowest prices,
and the loss of stable pharmacist-customer relationships
will make individual attention - and certainly the practice
of monitoring - impossible. Finally, it is argued that
damage will be done to the professional image of the pharmacist.
This image, that of a skilled and specialized craftsman,
attracts talent to the profession and reinforces the better
habits of those who are in it. Price advertising, it is
said, will reduce the pharmacist's status to that of a
mere retailer. 23
The strength of these proffered justifications
is greatly undermined by the fact that high professional
standards, to a substantial extent, are guaranteed by
the close regulation to which pharmacists in Virginia
are subject. And this case concerns the retail sale by
the pharmacist more than it does his professional standards.
Surely, any pharmacist guilty of professional dereliction
that actually endangers his customer will promptly lose
his [425 U.S. 748, 769] license. At the same time, we
cannot discount the Board's justifications entirely. The
Court regarded justifications of this type sufficient
to sustain the advertising bans challenged on due process
and equal protection grounds in Head v. New Mexico Board,
supra; Williamson v. Lee Optical Co., supra; and Semler
v. Dental Examiners, supra.
The challenge now made, however, is based
on the First Amendment. This casts the Board's justifications
in a different light, for on close inspection it is seen
that the State's protectiveness of its citizens rests
in large measure on the advantages of their being kept
in ignorance. The advertising ban does not directly affect
professional standards one way or the other. It affects
them only through the reactions it is assumed people will
have to the free flow of drug price information. There
is no claim that the advertising ban in any way prevents
the cutting of corners by the pharmacist who is so inclined.
That pharmacist is likely to cut corners in any event.
The only effect the advertising ban has on him is to insulate
him from price competition and to open the way for him
to make a substantial, and perhaps even excessive, profit
in addition to providing an inferior service. The more
painstaking pharmacist is also protected but, again, it
is a protection based in large part on public ignorance.
It appears to be feared that if the pharmacist
who wishes to provide low cost, and assertedly low quality,
services is permitted to advertise, he will be taken up
on his offer by too many unwitting customers. They will
choose the low-cost, low-quality service and drive the
"professional" pharmacist out of business. They
will respond only to costly and excessive advertising,
and end up paying the price. They will go from one pharmacist
to another, following the discount, and destroy the pharmacist-customer
relationship. They will lose respect for [425 U.S. 748,
770] the profession because it advertises. All this is
not in their best interests, and all this can be avoided
if they are not permitted to know who is charging what.
There is, of course, an alternative to this
highly paternalistic approach. That alternative is to
assume that this information is not in itself harmful,
that people will perceive their own best interests if
only they are well enough informed, and that the best
means to that end is to open the channels of communication
rather than to close them. If they are truly open, nothing
prevents the "professional" pharmacist from
marketing his own assertedly superior product, and contrasting
it with that of the low-cost, high-volume prescription
drug retailer. But the choice among these alternative
approaches is not ours to make or the Virginia General
Assembly's. It is precisely this kind of choice, between
the dangers of suppressing information, and the dangers
of its misuse if it is freely available, that the First
Amendment makes for us. Virginia is free to require whatever
professional standards it wishes of its pharmacists; it
may subsidize them or protect them from competition in
other ways. Cf. Parker v. Brown, 317 U.S. 341 (1943).
But it may not do so by keeping the public in ignorance
of the entirely lawful terms that competing pharmacists
are offering. In this sense, the justifications Virginia
has offered for suppressing the flow of prescription drug
price information, far from persuading us that the flow
is not protected by the First Amendment, have reinforced
our view that it is. We so hold.
VI
In concluding that commercial speech, like other varieties,
is protected, we of course do not hold that it can never
be regulated in any way. Some forms of commercial speech
regulation are surely permissible. We mention a few only
to make clear that they are not before us and therefore
are not foreclosed by this case. [425 U.S. 748, 771]
There is no claim, for example, that the
prohibition on prescription drug price advertising is
a mere time, place, and manner restriction. We have often
approved restrictions of that kind provided that they
are justified without reference to the content of the
regulated speech, that they serve a significant governmental
interest, and that in so doing they leave open ample alternative
channels for communication of the information. Compare
Grayned v. City of Rockford, 408 U.S. 104, 116 (1972);
United States v. O'Brien, 391 U.S. 367, 377 (1968); and
Kovacs v. Cooper, 336 U.S. 77, 85 -87 (1949), with Buckley
v. Valeo, 424 U.S. 1 ; Erznoznik v. City of Jacksonville,
422 U.S. 205, 209 (1975); Cantwell v. Connecticut, 310
U.S., at 304 -308; and Saia v. New York, 334 U.S. 558,
562 (1948). Whatever may be the proper bounds of time,
place, and manner restrictions on commercial speech, they
are plainly exceeded by this Virginia statute, which singles
out speech of a particular content and seeks to prevent
its dissemination completely.
Nor is there any claim that prescription
drug price advertisements are forbidden because they are
false or misleading in any way. Untruthful speech, commercial
or otherwise, has never been protected for its own sake.
Gertz v. Robert Welch, Inc., 418 U.S. 323, 340 (1974);
Konigsberg v. State Bar, 366 U.S. 36, 49 , and n. 10 (1961).
Obviously, much commercial speech is not provably false,
or even wholly false, but only deceptive or misleading.
We foresee no obstacle to a State's dealing effectively
with this problem. 24 The First Amendment, [425 U.S. 748,
772] as we construe it today, does not prohibit the State
from insuring that the stream of commercial information
flow cleanly as well as freely. See, for example, Va.
Code Ann. 18.2-216 (1975).
Also, there is no claim that the transactions
proposed in the forbidden advertisements are themselves
illegal in any way. Cf. Pittsburgh Press Co. v. Human
Relations Comm'n, 413 U.S. 376 (1973); United States [425
U.S. 748, 773] v. Hunter, 459 F.2d 205 (CA4), cert. denied,
409 U.S. 934 (1972). Finally, the special problems of
the electronic broadcast media are likewise not in this
case. Cf. Capitol Broadcasting Co. v. Mitchell, 333 F.
Supp. 582 (DC 1971), aff'd sub nom. Capitol Broadcasting
Co. v. Acting Attorney General, 405 U.S. 1000 (1972).
What is at issue is whether a State may
completely suppress the dissemination of concededly truthful
information about entirely lawful activity, fearful of
that information's effect upon its disseminators and its
recipients. Reserving other questions, 25 we conclude
that the answer to this one is in the negative.
The judgment of the District Court is affirmed.
It is so ordered.
|